Industry
Biotechnology
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Avi Kapoor
August 29, 2024 | 5:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 11:01 am
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 6:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 10:09 am
Portfolio Pulse from Avi Kapoor
July 22, 2024 | 3:29 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:12 am
Portfolio Pulse from Benzinga Insights
May 03, 2024 | 4:31 pm
Portfolio Pulse from Avi Kapoor
April 30, 2024 | 5:24 pm
Portfolio Pulse from Benzinga Insights
April 30, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
April 12, 2024 | 12:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.